| Sign In to gain access to subscriptions and/or personal tools. |
Alternative Strategies for Toxicity Testing of Species-Specific BiopharmaceuticalsFrom Amgen Inc, Thousand Oaks, California; Centocor Research & Development, Inc, Radnor, Pennsylvania; Genzyme, Framingham, Massachusetts; Genentech Inc, South San Francisco, California; and Taligen Therapeutics, Cambridge, Massachusetts. Correspondence: Please address correspondence to Jeanine L. Bussiere, PhD, DABT, Scientific Executive Director, Toxicology, Amgen Inc, One Amgen Center Dr, MS 29-2-A, Thousand Oaks, CA 91320-1799; e-mail:jeanine.bussiere{at}amgen.com. Although toxicology studies should always be conducted in pharmacologically relevant species, the specificity of many biopharmaceuticals can present challenges in identification of a relevant species. In certain cases, that is, when the clinical product is active only in humans or chimpanzees, or if the clinical candidate is active in other species but immunogenicity limits the ability to conduct a thorough safety assessment, alternative approaches to evaluating the safety of a biopharmaceutical must be considered. Alternative approaches, including animal models of disease, genetically modified mice, or use of surrogate molecules, may improve the predictive value of preclinical safety assessments of species-specific biopharmaceuticals, although many caveats associated with these models must be considered. Because of the many caveats that are discussed in this article, alternative approaches should only be used to evaluate safety when the clinical candidate cannot be readily tested in at least one relevant species to identify potential hazards.
Key Words: alternate strategies • biologics • biopharmaceuticals • genetically modified mice • homologous proteins • surrogate molecules
International Journal of Toxicology, Vol. 28, No. 3,
230-253 (2009) |
||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
